See the DrugPatentWatch profile for Inlyta
Inlyta is available for prescription use. The drug is manufactured by Pfizer [1].
How is Inlyta typically administered?
Inlyta is administered orally, meaning it is taken by mouth. It is available in tablet form [2].
What is Inlyta approved to treat?
Inlyta (axitinib) is approved for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer, in patients who have received prior systemic therapy [3].
What is the mechanism of action for Inlyta?
Inlyta is a potent and selective tyrosine kinase inhibitor. It targets vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. By inhibiting these receptors, Inlyta blocks tumor-mediated angiogenesis, which is the process by which tumors form new blood vessels to grow and spread [3].
What are the key clinical trial findings for Inlyta?
In clinical trials, Inlyta demonstrated an improvement in progression-free survival (PFS) in patients with advanced RCC who had progressed after prior treatment with a VEGF-targeted therapy [3].
How does Inlyta compare to other treatments for advanced renal cell carcinoma?
Inlyta is indicated for patients who have already received prior systemic therapy for advanced RCC. Its efficacy is measured against established benchmarks for second-line treatment of this cancer [3]. Comparative effectiveness studies may provide further insights into its position relative to other agents.
When does Inlyta's patent protection expire?
Patent information for Inlyta can be found on DrugPatentWatch.com, which tracks patent expirations and exclusivity periods for pharmaceuticals [4]. Specific patent expiry dates are subject to litigation and regulatory decisions.
What are the potential side effects of Inlyta?
Common side effects of Inlyta include diarrhea, fatigue, hypertension (high blood pressure), decreased appetite, nausea, hoarseness, and hand-foot syndrome [2][3]. Serious side effects can include arterial or venous thromboembolic events, heart failure, and gastrointestinal perforation or fistula [3].
Are there any specific warnings or precautions for Inlyta?
Patients taking Inlyta should be monitored for hypertension, which can be severe and may require dose adjustment or interruption. There is also a risk of cardiac dysfunction, bleeding events, and thyroid dysfunction [3]. Healthcare providers should discuss the risks and benefits of Inlyta with patients before initiating treatment.
What is the typical dosage of Inlyta?
The recommended starting dose of Inlyta is 5 mg taken orally twice daily. Dosage adjustments may be necessary based on tolerability and blood pressure [3].
Where can I find more detailed information on Inlyta's availability and prescribing information?
Detailed prescribing information, including indications, dosage, administration, warnings, precautions, and contraindications, is available from the manufacturer and regulatory agencies. DrugPatentWatch.com also offers resources related to drug patents and market exclusivity [4].
Sources:
[1] https://www.drugpatentwatch.com/drugs/inlyta
[2] https://www.drugpatentwatch.com/drugs/inlyta/patient-information
[3] https://www.drugpatentwatch.com/drugs/inlyta/prescribing-information
[4] https://www.drugpatentwatch.com/